AU2017229530B2 - Glucagon and GLP-1 co-agonists for the treatment of obesity - Google Patents

Glucagon and GLP-1 co-agonists for the treatment of obesity Download PDF

Info

Publication number
AU2017229530B2
AU2017229530B2 AU2017229530A AU2017229530A AU2017229530B2 AU 2017229530 B2 AU2017229530 B2 AU 2017229530B2 AU 2017229530 A AU2017229530 A AU 2017229530A AU 2017229530 A AU2017229530 A AU 2017229530A AU 2017229530 B2 AU2017229530 B2 AU 2017229530B2
Authority
AU
Australia
Prior art keywords
dose
peptide
glp
less
glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017229530A
Other languages
English (en)
Other versions
AU2017229530A1 (en
Inventor
Philip AMBERY
Maria Aleksandra Bednarek
Lutz Ulrich Jermutus
Marcella PETRONE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2017229530A1 publication Critical patent/AU2017229530A1/en
Priority to AU2020202381A priority Critical patent/AU2020202381A1/en
Application granted granted Critical
Publication of AU2017229530B2 publication Critical patent/AU2017229530B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2017229530A 2016-03-10 2017-03-10 Glucagon and GLP-1 co-agonists for the treatment of obesity Ceased AU2017229530B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020202381A AU2020202381A1 (en) 2016-03-10 2020-04-03 Glucagon and glp-1 co-agonists for the treatment of obesity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306121P 2016-03-10 2016-03-10
US62/306,121 2016-03-10
PCT/EP2017/055679 WO2017153575A1 (en) 2016-03-10 2017-03-10 Glucagon and glp-1 co-agonists for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202381A Division AU2020202381A1 (en) 2016-03-10 2020-04-03 Glucagon and glp-1 co-agonists for the treatment of obesity

Publications (2)

Publication Number Publication Date
AU2017229530A1 AU2017229530A1 (en) 2018-10-25
AU2017229530B2 true AU2017229530B2 (en) 2020-05-07

Family

ID=58266629

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017229530A Ceased AU2017229530B2 (en) 2016-03-10 2017-03-10 Glucagon and GLP-1 co-agonists for the treatment of obesity
AU2020202381A Abandoned AU2020202381A1 (en) 2016-03-10 2020-04-03 Glucagon and glp-1 co-agonists for the treatment of obesity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020202381A Abandoned AU2020202381A1 (en) 2016-03-10 2020-04-03 Glucagon and glp-1 co-agonists for the treatment of obesity

Country Status (19)

Country Link
US (3) US10676517B2 (https=)
EP (1) EP3426284B1 (https=)
JP (2) JP7237590B6 (https=)
KR (2) KR20220150416A (https=)
CN (1) CN108697769A (https=)
AR (1) AR107890A1 (https=)
AU (2) AU2017229530B2 (https=)
BR (1) BR112018067731A2 (https=)
CA (1) CA3015922A1 (https=)
EA (1) EA201891946A1 (https=)
ES (1) ES2983409T3 (https=)
IL (1) IL261528B2 (https=)
MX (1) MX2018010640A (https=)
MY (1) MY191321A (https=)
NZ (1) NZ746784A (https=)
SG (2) SG11201806342SA (https=)
TW (1) TWI793069B (https=)
WO (1) WO2017153575A1 (https=)
ZA (1) ZA201806637B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139613A1 (en) * 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
EA202290107A1 (ru) 2019-07-01 2022-03-29 Медиммун Лимитед Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
KR102812908B1 (ko) 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
JP2023505126A (ja) * 2019-12-03 2023-02-08 メディミューン，エルエルシー 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑
CN115397455A (zh) * 2020-01-16 2022-11-25 上海仁会生物制药股份有限公司 Glp-1给药方案
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
KR20230005289A (ko) 2020-04-24 2023-01-09 베링거 인겔하임 인터내셔날 게엠베하 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체
CA3201539A1 (en) * 2020-12-07 2022-06-16 Vyjayanthi Krishnan Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
US20230374096A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
KR20250067206A (ko) 2023-11-07 2025-05-15 주식회사 천농바이오푸드 대사성 질환의 예방, 개선 또는 치료 효과를 갖는 채소 추출복합물 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094337A1 (en) * 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2012050923A2 (en) * 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2014091316A2 (en) * 2012-12-11 2014-06-19 Medimmune Limited Glucagon/glp-1 agonists for the treatment of obesity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
AU2010272944B2 (en) * 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
DK2694095T3 (en) * 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AU2013366692B2 (en) * 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094337A1 (en) * 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2012050923A2 (en) * 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
WO2014091316A2 (en) * 2012-12-11 2014-06-19 Medimmune Limited Glucagon/glp-1 agonists for the treatment of obesity

Also Published As

Publication number Publication date
KR20180120739A (ko) 2018-11-06
AU2020202381A1 (en) 2020-04-30
AR107890A1 (es) 2018-06-28
ZA201806637B (en) 2019-07-31
KR102460198B1 (ko) 2022-10-31
JP7237590B6 (ja) 2023-03-28
IL261528B2 (en) 2023-09-01
US10676517B2 (en) 2020-06-09
KR20220150416A (ko) 2022-11-10
EP3426284B1 (en) 2024-05-08
CA3015922A1 (en) 2017-09-14
SG11201806342SA (en) 2018-08-30
IL261528A (en) 2018-10-31
EP3426284A1 (en) 2019-01-16
WO2017153575A1 (en) 2017-09-14
NZ746784A (en) 2022-11-25
IL261528B1 (en) 2023-05-01
TW201733613A (zh) 2017-10-01
EA201891946A1 (ru) 2019-04-30
TWI793069B (zh) 2023-02-21
SG10202109721PA (en) 2021-10-28
CN108697769A (zh) 2018-10-23
US20220041681A1 (en) 2022-02-10
JP7237590B2 (ja) 2023-03-13
US20190185537A1 (en) 2019-06-20
ES2983409T3 (es) 2024-10-23
JP2019510014A (ja) 2019-04-11
BR112018067731A2 (pt) 2019-01-08
MY191321A (en) 2022-06-15
JP2023011864A (ja) 2023-01-24
AU2017229530A1 (en) 2018-10-25
US20200354426A1 (en) 2020-11-12
MX2018010640A (es) 2019-06-13

Similar Documents

Publication Publication Date Title
AU2017229530B2 (en) Glucagon and GLP-1 co-agonists for the treatment of obesity
AU2017261505B2 (en) Glucagon/glp-1 agonists for the treatment of obesity
JP2019510014A5 (https=)
WO2008152403A1 (en) Glucagon analogues
JP2013511287A (ja) ポリペプチド・コンジュゲート
EA043848B1 (ru) Коагонисты глюкагона и glp-1 для лечения ожирения
NZ785999A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
US20230012936A1 (en) Combination therapy using glucagon and glp-1 co-agonists for the treatment of obesity
HK40010017A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK40010017B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
HK1216179B (en) Glucagon/glp-1 agonists for the treatment of obesity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired